{"id":1487,"date":"2024-07-23T10:38:37","date_gmt":"2024-07-23T02:38:37","guid":{"rendered":"https:\/\/flcube.com\/?p=1487"},"modified":"2024-12-03T18:58:07","modified_gmt":"2024-12-03T10:58:07","slug":"aligos-therapeutics-and-xiamen-amoytop-biotech-partner-to-test-hepatitis-b-combination-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1487","title":{"rendered":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy"},"content":{"rendered":"\n

Aligos Therapeutics Inc. (NASDAQ: ALGS<\/a>), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos’ ALG-000184 with Amoytop’s Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.<\/p>\n\n\n\n

ALG-000184, developed by Aligos, is a potent oral small-molecule capsid assembly modulator (CAM-E) that is currently in a Phase Ib trial. The drug has shown promising results, demonstrating best-in-class reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg without any viral breakthrough to date. Amoytop’s Pegbing, the world’s first 40kD pegylated interferon \u03b1-2b injection, functions by inhibiting viral replication and enhancing immune responses. It is primarily used as a first-line antiviral treatment for CHB in clinical settings. The collaboration between the two companies seeks to leverage the synergistic potential of the combined therapy to improve the clinical cure rate for hepatitis B virus.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[162,470,1238,25,89],"class_list":["post-1487","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-aligos-therapeutics","tag-amoytop-biotech","tag-nasdaq-algs","tag-potential-first-in-class","tag-viral-hepatitis"],"yoast_head":"\nAligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos' ALG-000184 with Amoytop's Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-23T02:38:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T10:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy\",\"datePublished\":\"2024-07-23T02:38:37+00:00\",\"dateModified\":\"2024-12-03T10:58:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aligos Therapeutics\",\"Amoytop Biotech\",\"NASDAQ: ALGS\",\"Potential first-in-class\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1487#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1487\",\"name\":\"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-23T02:38:37+00:00\",\"dateModified\":\"2024-12-03T10:58:07+00:00\",\"description\":\"Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos' ALG-000184 with Amoytop's Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1487\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy - Insight, China's Pharmaceutical Industry","description":"Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos' ALG-000184 with Amoytop's Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1487","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1487","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-23T02:38:37+00:00","article_modified_time":"2024-12-03T10:58:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy","datePublished":"2024-07-23T02:38:37+00:00","dateModified":"2024-12-03T10:58:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1487"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aligos Therapeutics","Amoytop Biotech","NASDAQ: ALGS","Potential first-in-class","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1487#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1487","url":"https:\/\/flcube.com\/?p=1487","name":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-23T02:38:37+00:00","dateModified":"2024-12-03T10:58:07+00:00","description":"Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos' ALG-000184 with Amoytop's Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1487"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1487"}],"version-history":[{"count":4,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1487\/revisions"}],"predecessor-version":[{"id":16462,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1487\/revisions\/16462"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}